リネゾリド 化学特性,用途語,生産方法
外観
白色～わずかにうすい黄色, 結晶性粉末～粉末
溶解性
メタノールに可溶
用途
オキサゾリジノン系抗菌剤で
す。細菌リボソーム 50S に結合し、タンパ
ク質合成を阻害します。リボソーム伸長反応、
ペプチド結合の合成は阻害しません。バンコ
マイシン耐性腸球菌（VRE）及びメチシリン
耐性黄色球菌（MRSA）に対して、抗菌作用
を示します。
用途
オキサゾリジノン系抗生物質です。細菌のポリペプチド鎖伸長開始前のタンパク質合成を阻害
します。
用途
リネゾリド (linezolid) は抗生物質の一種で、バンコマイシンに対する薬剤耐性を獲得したバンコマイシン耐性腸球菌(Vancomycin-resistant Enterococci, VRE)および黄色ブドウ球菌 (Vancomycin-resistant Staphylococcus aureus, VRSA) に有効な新薬として登場した。オキサゾリジノン系合成抗菌剤という新系統の抗生物質であり。
リンコサミド系（クリンダマイシン）、ストレプトグラミン系と抗菌活性機序および抗菌スペクトルが類似しているため、同じグループに分類される。
リボソームの50Sサブユニットに結合して70S開始複合体の形成を阻害することにより、細菌の蛋白合成が阻害され、菌の増殖を抑制する。
効能
抗菌薬, タンパク質合成阻害薬
商品名
ザイボックス (ファイザー); ザイボックス (ファイザー); リネゾリド (光製薬)
説明
Linezolid reached the US market for the treatment of patients with infections caused by
serious Gram-positive pathogens, particularly skin and soft tissue infections, communityacquired
pneumonia and vancomycin-resistant enterococcal infections. Linezolid is the
(S)-enantiomer of an oxazolidin-2-one synthesized in a multistep process from 3,4-
difluoronitrobenzene, the key step being the cyclization of a carbamate, using a chiral
epoxyester, into an enantiomerically pure oxazolidin-2-one. Linezolid can be considered as
the first of a new class of antibacterial agents known as oxazolidinones, its mechanism of
action being related to the inhibition of early ribosomal protein synthesis without directly
inhibiting DNA or RNA synthesis. In vitro studies demonstrated that linezolid was effective,
at potency levels similar to vancomycin, against staphylococcal, streptococcal and
pneumococcal infections (MIC values in the range of 0.5 to 2 μg/ml), enterococcal species
including VRE and VSE (MIC values about 4 μg/ml), but also other vancomycin-resistant
bacteria. Linezolid is rapidly absorbed orally, its bioavailability is nearly complete at 250
mg dose giving a Cmax to MIC ratio sufficient to have pathogenic strain eradication in the
clinical setting. It is considered that this new promising agent may offer new options for
therapy of multi-drug infections.
化学的特性
White Solid
使用
Linezolid has been used in checkerboard-type drug combination MIC (minimum inhibitory concentrations) assay to determine whether ivacaftor shows positive interaction with linezolid. It has been used for the determination of minimum biofilm inhibitory concentration and for the treatment of Mycobacterium abscessus-infected
Drosophila melanogaster w1118 flies.
定義
ChEBI: An organofluorine compound that consists of 1,3-oxazolidin-2-one bearing an N-3-fluoro-4-(morpholin-4-yl)phenyl group as well as an acetamidomethyl group at position 5. A synthetic antibacterial agent that inhibits bacterial protein synt
esis by binding to a site on 23S ribosomal RNA of the 50S subunit and prevents further formation of a functional 70S initiation complex.
獲得抵抗性
Isolates of Staph. aureus and E. faecalis for which the MIC of linezolid is raised have been obtained following serial exposure to gradients of the drug. However, induction of resistance requires many passages over several weeks. Resistance in these laboratory mutants is associated with modifications of the 23S rRNA gene.
Overall, resistance rates in clinical isolates are very low at <0.5%. Resistance is reported primarily in coagulase-negative staphylococci (1.77%) and enterococci (1.13%; mostly E. faecium), with exceptionally low resistance rates in Staph. aureus (0.06%). Risk factors for emergence of resistance include prolonged use of the drug, the presence of irremovable indwelling devices, sequestered sites of infection and low-dose therapy for infections caused by vancomycin-resistant enterococci or methicillin-resistant Staph. aureus. Resistance in clinical isolates is most often associated with gene mutations in which guanosine is replaced by uracil in the 23S rRNA. Nosocomial clonal spread of such mutants has been described in coagulase-negative staphylococci and enterococci. Resistance conferred by a novel mobile element, cfr, has been described in two isolates of staphylococci.
一般的な説明
Linezolid (Zyvox) is an oxazolidinedione-type antibacterialagent that inhibits bacterial protein synthesis. It acts in theearly translation stage, preventing the formation of a functionalinitiation complex. Linezolid binds to the 30S and 70Sribosomal subunits and prevents initiation complexes involvingthese subunits. Collective data suggest that the oxazolidindionespartition their ribosomal interaction between thetwo subunits. Formation of the early tRNAfMet-mRNA-70Sor 30S is prevented. Linezolid is a newer synthetic agent, andhence, cross-resistance between the antibacterial agent andother inhibitors of bacterial protein synthesis has notbeen seen.
Linezolid possesses a wide spectrum of activity againstGram-positive organisms, including MRSA, penicillin-resistantpneumococci, and vancomycin-resistant Enterococcusfaecalis and E. faecium. Anaerobes such as Clostridium,Peptostreptococcus, and Prevotella spp. are sensitive tolinezolid.Linezolid is a bacteriostatic agent against most susceptibleorganisms but displays bactericidal activity against somestrains of pneumococci, B. fragilis, and Clostridiumperfringens.The indications for linezolid are for complicated anduncomplicated skin and soft-tissue infections, communityandhospital-acquired pneumonia, and drug-resistant Grampositiveinfections.
応用例（製薬）
A synthetic oxazolidinone available for oral or intravenous administration. Soluble in water at a pH range of 5–9. Aqueous solutions (2 g/L) are stable at 25°C, 4°C and ?20°C for at least 3 months.
生物活性
Oxazolidinone antibiotic. Inhibits bacterial protein synthesis prior to chain initiation. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo .
作用機序
The mechanism of action is inhibition of protein synthesis, but at a stage different from that of
other protein synthesis inhibitors. The oxazolidinones bind to the 23S rRNA of the 50S subparticle to prevent
formation of a functional 70S initiation complex. It is considered to be bacteriostatic against
enterococci and staphylococci but bacteriocidal against streptococci. Resistance to oxazolidinones is
encountered in the clinic because of a mutation in the 23S rRNA. This is believed to distort the linezolid
binding site. Gram-negative microorganisms are intrinsically resistant to linezolid because of the presence of
endogenous efflux pumps that keep it from accumulating in the cells.
臨床応用
Linezolid is primarily used for the treatment of infections caused, or likely to be caused, by methicillin-resistant Staph. aureus, vancomycin-resistant enterococci and penicillin resistant Str. pneumoniae. Combination therapy with an antimicrobial active against Gram-negative bacteria is indicated if concomitant infection with a Gram-negative pathogen is suspected or confirmed.
Outside of licensed indications, it has been used in the treatment of bone and joint infections, endocarditis, central nervous system infections, infections in neutropenic patients and drug-resistant tuberculosis.
代謝
Linezolid is well absorbed orally and is
generally well tolerated; however, some severe cases of reversible blood dyscrasias have been noted,
resulting in a package insert warning that complete blood counts should be monitored weekly, especially in
patients with poorly draining infections and who are receiving prolonged therapy with the drug. Some interference with monoamine oxidase action has been seen, so patients should be cautious about ingesting
tyramine-rich foods. Coadministration with adrenergic and serotonergic agents also is unadvisable.
Additionally, lactic acidosis has been reported in patients receiving linezolid. Significant oxidative
metabolism of the morpholine ring occurs but is not caused by cytochrome P450, so it does not interfere with
other drugs metabolized by this system.
リネゾリド 上流と下流の製品情報
原材料
準備製品